Solutions
keyboard_arrow_downServices
keyboard_arrow_downSupport & Resources
keyboard_arrow_downCompany
keyboard_arrow_downContact
Get in touch to discover more
To find out more about the Acute Kidney Injury , enquire now.
UTI Testing Made Simple
urology Quick turnaround time of 150 minutes compared to 72 hours minimum for standard urine culture, beneficial for both the patient and for the containment of the most common UTIs
urology Convenient 4 step process from sample entry to results. Suitable for use in laboratory and non-laboratory settings
urology Detect 16 different uropathogens and identify the presence of 7 antimicrobial resistance genes all from one single urine sample
Clinical Significance
Urinary tract infections (UTIs) are highly prevalent infections acquired both in the community and hospital settings. The widespread use of antibiotics has led to an alarming rise in UTIs caused by organisms that are resistant to multiple drugs, affecting approximately 150 million people worldwide each year.
UTIs can be categorised as either uncomplicated or complicated, depending on various factors such as anatomical or functional abnormalities within the urinary tract, comorbidities, recurrent UTIs, catheter-associated UTIs, and urosepsis.
A single native urine sample, along with the Vivalytic PCR-based assay, for simultaneous qualitative detection of causative UTI bacterial and fungal pathogens can detect 16 different uropathogens and identify the presence of 7 antimicrobial resistance genes, allowing for a swift and effective treatment plan to begin. With a rapid time-to-result of 2.5 hours and capable of identifying a multitude of bacterial targets, the UTI panel on Vivalytic leads to improved patient outcomes and effective management of urinary tract infections.
Features
Sample Type: Native Urine
Sample Volume: 300 μl
Detection Method: Randox Biochip Technology (end-point PCR)
Time to result: 2.5 Hours
Detectable Pathogens
| GRAM-NEGATIVE BACTERIAL SPECIES |
|---|
| Acinetobacter baumannii |
| Enterobacter cloacae |
| Escherichia coli |
| Escherichia coli |
| Klebsiella aerogenes |
| Klebsiella oxytoca |
| Klebsiella pneumoniae |
| Morganella morganii |
| Proteus spp. |
| Providencia stuartii |
| Pseudomonas aeruginosa |
| GRAM-POSITIVE BACTERIAL SPECIES |
|---|
| Enterococcus faecalis |
| Enterococcus faecium |
| Staphylococcus aureus |
| Staphylococcus epidermidis |
| Staphylococcus saprophyticus |
| Streptococcus agalactiae |
| ANTIMICROBIAL RESISTANCE GENES |
|---|
| TRIMETHOPRIM RESISTANCE |
| dfrA1 |
| dfrA5 |
| dfrA12 |
| dfrA17 |
| METHICILLIN RESISTANCEVANCOMYCIN RESISTANCE |
| mecA |
| Vancomycin Resistance |
| vanA |
| vanB |
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.